LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT–PCR and immunohistochemical analysis
2003

LRIG1 and EGFR in Kidney Cancer

Sample size: 31 publication Evidence: moderate

Author Information

Author(s): Thomasson M, Hedman H, Guo D, Ljungberg B, Henriksson R

Primary Institution: Umeå University Hospital

Hypothesis

The study aims to evaluate the expression of LRIG1 in renal cell carcinoma (RCC) and its relationship with EGFR expression.

Conclusion

The study found that LRIG1 is underexpressed in RCC and that the ratio of EGFR to LRIG1 is increased, suggesting that LRIG1 may act as a tumor suppressor.

Supporting Evidence

  • LRIG1 expression was decreased in the majority of RCC tumors compared to normal kidney tissue.
  • The EGFR/LRIG1 ratio was increased at least 2.5-fold in all tumors matched with corresponding kidney cortex.
  • A tendency for lower LRIG1 expression was observed in grade 4 tumors compared to lower grade tumors.

Takeaway

This study looked at how two proteins, LRIG1 and EGFR, behave in kidney cancer. It found that one protein is lower in cancer cells, which might help the other protein promote cancer.

Methodology

The study used quantitative RT-PCR and immunohistochemistry to analyze RNA and protein expression in tumor and normal kidney tissues.

Limitations

The study had a limited sample size of 31 patients, which may affect the generalizability of the findings.

Participant Demographics

{"total_patients":31,"sex_ratio":"17 male / 14 female","age_range":"36–85 years","tumor_types":{"conventional":18,"papillary":10,"chromophobe":3}}

Statistical Information

P-Value

0.0881

Statistical Significance

p=0.0881

Digital Object Identifier (DOI)

10.1038/sj.bjc.6601208

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication